Validated Outcomes Omada's programs are clinically validated with outcomes across multiple peer reviewed studies, showing lasting behavior change and reduced healthcare costs, delivering measurable ROI for employers, health plans, PBMs, and government programs.

GLP1 Growth Strategic emphasis on GLP1 journeys, strengthened by a Lilly partnership and a cash pay option for GLP1 medications launched in 2026, indicating a clear path to broader access and payer alignment for GLP1 care.

Financial Momentum Strong growth trajectory and financial health, with a 2025 IPO raising capital and current revenue in the mid range, plus profitability in recent quarters, signaling capacity to scale partner programs and investments.

Tech Enabled Technology and data capabilities underpin program delivery, including SageMaker for AI ML, Gainsight for customer success, and Meal Map nutrition tooling, unlocking opportunities for data driven personalization and partner integrations.

Strategic Partnerships Broad and evolving partner ecosystem spanning Abbott, Lilly, employers, health plans, PBMs, and government agencies, with potential to expand through additional pharma collaborations, payer contracts, and public sector programs while leveraging a strong employer culture.